Educational Strategies for Advanced Kidney Disease
(THRiVE Trial)
Trial Summary
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It seems focused on educational strategies rather than medication changes.
What data supports the effectiveness of the treatment Educational Strategies for Advanced Kidney Disease?
Research shows that educational and empowerment programs can improve the quality of life for kidney patients by helping them manage their own care better. Motivational interviewing, a part of this treatment, has been effective in encouraging behavior change and improving patient outcomes in kidney disease management.12345
Is the educational strategy for advanced kidney disease safe for humans?
How is the treatment 'Educational Strategies for Advanced Kidney Disease' different from other treatments for kidney disease?
This treatment is unique because it combines educational materials and motivational interviewing to help patients with advanced kidney disease understand their options, including conservative management and advance care planning, which are often overlooked in standard care. It focuses on culturally and linguistically tailored education, making it more accessible and relevant to diverse patient populations.1391011
What is the purpose of this trial?
The focus of this study is on vascular access for hemodialysis. This is a randomized clinical trial testing 3 educational approaches to help patients with advanced chronic kidney disease prepare for placement of hemodialysis vascular access. Study participants will each be assigned to one of the 3 approaches: 1) "Education", in which participants will be given a video and brochure that provide information about the types of vascular access and what can be expected before and after the vascular access is placed, 2) "Education-Plus", in which participants will be given the video and brochure and will also have sessions by telehealth with a motivational interviewing coach to provide additional support around vascular access placement, and 3) "Usual Care", in which participants will have the usual education provided by their kidney doctor and clinic staff just as if they were not in the study. Participants in all 3 groups will be asked to complete questionnaires by telephone and may be invited to be interviewed about their experience with the study intervention at the end of the study. Study participation will last for about 12 months, with most of the study activities taking place during the first 3 months.
Research Team
Deidra Crews, MD, ScM
Principal Investigator
Johns Hopkins University
Laura M. Dember, MD
Principal Investigator
University of Pennsylvania
Jennifer Flythe, MD
Principal Investigator
University of North Carolina, Chapel Hill
Eligibility Criteria
This trial is for adults over 18 with advanced chronic kidney disease who've discussed hemodialysis with their doctor, visited a nephrologist in the last 18 months, and have specific lab results indicating severe kidney function decline. It's not for those already planning different kidney failure treatments or who can't use the educational materials due to cognitive or visual impairments.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Education Phase
Participants receive educational materials and support based on their assigned group: Education, Education-Plus, or Usual Care.
Follow-up
Participants are monitored for outcomes such as vascular access evaluation and decision self-efficacy.
Treatment Details
Interventions
- Educational Materials
- Motivational Interviewing
- Usual Care
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Pennsylvania
Lead Sponsor
Johns Hopkins University
Collaborator
University of North Carolina, Chapel Hill
Collaborator